Literature DB >> 10951443

Fatigue and its impact on patients with myasthenia gravis.

R H Paul1, R A Cohen, J M Goldstein, J M Gilchrist.   

Abstract

We have examined fatigue in myasthenia gravis (MG) by administering a measure of cognitive and physical fatigue to patients and control subjects before and after administration of a lengthy cognitive battery. Subjects also completed a scale that assessed the impact of fatigue on physical, social, and cognitive function. Results of the study revealed that MG patients experience significantly more cognitive and physical fatigue than do control subjects, and the patients' perceptions of both cognitive and physical fatigue increased significantly following completion of demanding cognitive work. Control subjects reported no significant change in fatigue. Furthermore, MG patients reported that fatigue produced mild to moderate effects on cognitive and social function and moderate effects on physical function. Results from this study indicate that cognitive fatigue is an important symptom of MG and that fatigue produces pervasive impairments in important aspects of patients' lives. Additional studies are needed to understand the neurobehavioral determinants of cognitive fatigue in this population. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  2000        PMID: 10951443     DOI: 10.1002/1097-4598(200009)23:9<1402::aid-mus11>3.0.co;2-b

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  14 in total

1.  Possible therapeutic vaccines for canine myasthenia gravis: implications for the human disease and associated fatigue.

Authors:  F Shawn Galin; Cheryl L Chrisman; James R Cook; Likang Xu; Patricia L Jackson; Brett D Noerager; Nathaniel M Weathington; J Edwin Blalock
Journal:  Brain Behav Immun       Date:  2006-11-20       Impact factor: 7.217

2.  Psychosocial aspects in myasthenic patients treated by plasmapheresis.

Authors:  Yu-Tai Chen; Yuanmay Chang; Hou-Chang Chiu; Jiann-Horng Yeh
Journal:  J Neurol       Date:  2011-02-02       Impact factor: 4.849

Review 3.  Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy.

Authors:  Benzi M Kluger; Lauren B Krupp; Roger M Enoka
Journal:  Neurology       Date:  2013-01-22       Impact factor: 9.910

4.  Fatigue in patients with myasthenia gravis.

Authors:  T M Alekseeva; Y V Gavrilov; O A Kreis; P O Valko; K P Weber; Y Valko
Journal:  J Neurol       Date:  2018-08-11       Impact factor: 4.849

5.  Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I.

Authors:  J S Kalkman; M L Schillings; S P van der Werf; G W Padberg; M J Zwarts; B G M van Engelen; G Bleijenberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

Review 6.  Fatigue in neuromuscular disorders: focus on Guillain-Barré syndrome and Pompe disease.

Authors:  J M de Vries; M L C Hagemans; J B J Bussmann; A T van der Ploeg; P A van Doorn
Journal:  Cell Mol Life Sci       Date:  2010-03       Impact factor: 9.261

7.  Major motor-functional determinants associated with poor self-reported health-related quality of life in myasthenia gravis patients.

Authors:  David Cioncoloni; Stefania Casali; Federica Ginanneschi; Marisa Carone; Boni Veronica; Alessandro Rossi; Fabio Giannini
Journal:  Neurol Sci       Date:  2016-04-01       Impact factor: 3.307

Review 8.  Fatigue as a symptom or comorbidity of neurological diseases.

Authors:  Iris-Katharina Penner; Friedemann Paul
Journal:  Nat Rev Neurol       Date:  2017-10-13       Impact factor: 42.937

9.  Does cardiovascular autonomic dysfunction contribute to fatigue in myasthenia gravis?

Authors:  A Elsais; E Kerty; K Russell; K Toska
Journal:  Physiol Res       Date:  2022-01-19       Impact factor: 1.881

10.  Health status in non-dystrophic myotonias: close relation with pain and fatigue.

Authors:  J Trip; J de Vries; G Drost; H B Ginjaar; B G M van Engelen; C G Faber
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.